Table 3.
Comorbidities, treatments and outcomes of patients with fibrillary glomerulonephritis at UNC Kidney Center compared to other cohorts
| Rosenstock. et al. [1], 2003 (n = 61) | Nasr et al [22], 2011(n =61) | Kalbermatter et al. [8], 2012 (n = 16) | Javaugue et al. [23], 2013 (n = 27) | UNC Kidney Center 2017 (n = 42) | |
|---|---|---|---|---|---|
| Comorbidities, % (n) | |||||
| Autoimmune disease | 5 (3) | 15 (10) | 13 (2) | 30 (8) | 13 (5/40) |
| Hepatitis B | – | – | – | – | 8 (2/26) |
| Hepatitis C | 17 (10) | 3 (2) | – | 7 (2) | 27 (7/26) |
| HIV | 0 | – | – | – | 5 (1/19) |
| Malignancies | 7 (4) | 23 (15) | 19 (3) | 7 (2) | 12 (6/40) |
| COPD | – | 5 (3) | – | 19 (5) | 13 (5/40) |
| Coronary artery disease | – | 9 (6) | – | – | 18 (7/39) |
| Diabetes mellitus | 20 (12) | 20 (13) | 6 (1) | 22 (6) | 28 (11/40) |
| Treatment, % (n) | |||||
| No treatment | – | 26 (16) | – | – | 7 (3) |
| Immediate hemodialysis | – | – | – | – | 7 (3) |
| RAAS blockade alone | – | 26 (16) | – | – | 24 (10) |
| RAAS blockade included | – | – | – | – | 36 (15) |
| Plasmapheresis | – | – | – | – | 2 (1) |
| Immunosuppressive therapy, % (n) | n = 20 (33%) | n = 29 (44%) | n = 13 (81%) | n = 13 (48%) | n = 20 (48%) |
| Rituximab | – | 10 (3) | – | 54 (7) | 75 (15) |
| Steroids included | – | 83 (24) | – | – | 40 (8) |
| Steroids alone | 45 (9) | 28 (8) | 62 (8) | 38 (5) | 5 (1) |
| Cyclosporine | 15 (3) | 7 (2) | 8 (1) | 31 (4) | 20 (4) |
| Cyclophosphamide | 40 (8) | 31 (9) | 38 (5) | 23 (3) | 10 (2) |
| MMF | – | 21 (6) | – | 8 (1) | 5 (1) |
| Bortezomib | – | – | – | 8 (1) | 10 (2) |
| Outcome, % (n) | n = 60 | n = 61 | n = 16 | n = 27 | n = 42 |
| Dialysis/ESKD | 45 (28) | 44 (27) | 38 (6) | 48 (13) | 36 (15) |
| Transplant | 4 (2) | 23 (14) | – | – | 10 (4) |
| Death | – | 20 (12) | 38 (6) | 19 (5) | 24 (10) |
COPD, chronic obstructive pulmonary disease; MMF, mycophenolate mofetil.